Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-06-30

AUTHORS

J S Thompson Coon, Z Liu, M Hoyle, G Rogers, C Green, T Moxham, K Welch, K Stein

ABSTRACT

Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-α)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63–1.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. More... »

PAGES

238-243

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167

DOI

http://dx.doi.org/10.1038/sj.bjc.6605167

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013222336

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19568242


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson Coon", 
        "givenName": "J S", 
        "id": "sg:person.0762650054.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650054.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Z", 
        "id": "sg:person.01265262475.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265262475.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoyle", 
        "givenName": "M", 
        "id": "sg:person.0647332044.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647332044.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rogers", 
        "givenName": "G", 
        "id": "sg:person.01174312663.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "C", 
        "id": "sg:person.01262712354.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262712354.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moxham", 
        "givenName": "T", 
        "id": "sg:person.0607771575.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607771575.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK", 
          "id": "http://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Welch", 
        "givenName": "K", 
        "id": "sg:person.01225701373.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225701373.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "K", 
        "id": "sg:person.01054372611.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2407-6-293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045174638", 
          "https://doi.org/10.1186/1471-2407-6-293"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-9-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011234840", 
          "https://doi.org/10.1186/1471-2407-9-34"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-06-30", 
    "datePublishedReg": "2009-06-30", 
    "description": "Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-\u03b1 (IFN-\u03b1)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-\u03b1) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63\u20131.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605167", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "101"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "renal cell carcinoma", 
      "progression-free survival", 
      "advanced metastatic renal cell carcinoma", 
      "cell carcinoma", 
      "clinical trials", 
      "indirect comparison", 
      "median progression-free survival", 
      "first-line treatment", 
      "effects of sunitinib", 
      "systematic literature search", 
      "further relevant studies", 
      "licensed indication", 
      "overall survival", 
      "clinical effectiveness", 
      "common comparator", 
      "STUDY SELECTION", 
      "bevacizumab", 
      "new agents", 
      "sunitinib", 
      "IFN", 
      "electronic databases", 
      "systematic review", 
      "literature search", 
      "relevant studies", 
      "data extraction", 
      "survival", 
      "treatment", 
      "carcinoma", 
      "conference proceedings", 
      "trials", 
      "patients", 
      "study", 
      "evidence", 
      "Win BUGS", 
      "quality assessment", 
      "intervention", 
      "reviewers", 
      "indications", 
      "review", 
      "agents", 
      "assessment", 
      "comparator", 
      "database", 
      "criteria", 
      "comparison", 
      "effect", 
      "significant advantages", 
      "search", 
      "use", 
      "combination", 
      "data", 
      "bibliography", 
      "effectiveness", 
      "validation", 
      "disagreement", 
      "accordance", 
      "proceedings", 
      "selection", 
      "online interface", 
      "discussion", 
      "Europe", 
      "extraction", 
      "terms", 
      "advantages", 
      "Bayesian Markov chain Monte Carlo", 
      "BUGS", 
      "interface", 
      "Markov chain Monte Carlo", 
      "paper", 
      "Monte Carlo"
    ], 
    "name": "Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness", 
    "pagination": "238-243", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013222336"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605167"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19568242"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605167", 
      "https://app.dimensions.ai/details/publication/pub.1013222336"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_482.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605167"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605167'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      112 URIs      102 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605167 schema:about N0d4810a3a7b9416ba7f6559f65da3f5f
2 N1b8b600d0ef941afa8fc9aa3aeb1f753
3 N1f93bce84e7248eb9e89546e1fe9d18f
4 N2be81d7c4318497f86e590174563dacb
5 N4446dc1c290d477aaf1493e502b2f209
6 N7504b637daf2433aa9f7e45e3f173e64
7 N793e11dbfd314c6d959d5b2cea2df41f
8 N82742bee836249c08667b8623038a697
9 N931a6b765cfc49a0821034e52c30db12
10 Nb8484ee51c5f458fb58118a354960281
11 Nbf9bedd04b0e4605ab9cfaa67e7e9b82
12 Nc96cbaad282b408fbae523122a4a0e07
13 Nd3255092b7b4490c83b1a4afc8851b1c
14 Nddc0cb38b1e04289b84ebd1301072eb3
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N9dd85fb1f7034a6388c8c51abcf45191
18 schema:citation sg:pub.10.1186/1471-2407-6-293
19 sg:pub.10.1186/1471-2407-9-34
20 schema:datePublished 2009-06-30
21 schema:datePublishedReg 2009-06-30
22 schema:description Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-α)) in the treatment of advanced metastatic RCC.Methods:Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.Results:Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63–1.0; P=0.0272).Conclusion:There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N9ae4d9231ad547bf9598e2185b6d3b86
26 Nde10a1bdbcf84b88b10232789f8151b5
27 sg:journal.1017082
28 schema:keywords BUGS
29 Bayesian Markov chain Monte Carlo
30 Europe
31 IFN
32 Markov chain Monte Carlo
33 Monte Carlo
34 STUDY SELECTION
35 Win BUGS
36 accordance
37 advanced metastatic renal cell carcinoma
38 advantages
39 agents
40 assessment
41 bevacizumab
42 bibliography
43 carcinoma
44 cell carcinoma
45 clinical effectiveness
46 clinical trials
47 combination
48 common comparator
49 comparator
50 comparison
51 conference proceedings
52 criteria
53 data
54 data extraction
55 database
56 disagreement
57 discussion
58 effect
59 effectiveness
60 effects of sunitinib
61 electronic databases
62 evidence
63 extraction
64 first-line treatment
65 further relevant studies
66 indications
67 indirect comparison
68 interface
69 intervention
70 licensed indication
71 literature search
72 median progression-free survival
73 metastatic renal cell carcinoma
74 new agents
75 online interface
76 overall survival
77 paper
78 patients
79 proceedings
80 progression-free survival
81 quality assessment
82 relevant studies
83 renal cell carcinoma
84 review
85 reviewers
86 search
87 selection
88 significant advantages
89 study
90 sunitinib
91 survival
92 systematic literature search
93 systematic review
94 terms
95 treatment
96 trials
97 use
98 validation
99 schema:name Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
100 schema:pagination 238-243
101 schema:productId Nc045069290b244688f05b10e7e02f3b2
102 Nc11a56dfbc0848c4af2b42d90b82a414
103 Nc8986539095149e6948f2beb03973a5b
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013222336
105 https://doi.org/10.1038/sj.bjc.6605167
106 schema:sdDatePublished 2022-09-02T15:52
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N05f5fad1b97448d6aef594a9699711ad
109 schema:url https://doi.org/10.1038/sj.bjc.6605167
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N05f5fad1b97448d6aef594a9699711ad schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N0d4810a3a7b9416ba7f6559f65da3f5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N1934035b895d4fa785ffeb081429cb26 rdf:first sg:person.01174312663.64
119 rdf:rest Ne8e66cbed7d94fa0b5dc4eb20d552cce
120 N1b8b600d0ef941afa8fc9aa3aeb1f753 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Randomized Controlled Trials as Topic
122 rdf:type schema:DefinedTerm
123 N1f93bce84e7248eb9e89546e1fe9d18f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Indoles
125 rdf:type schema:DefinedTerm
126 N2be81d7c4318497f86e590174563dacb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Clinical Trials, Phase III as Topic
128 rdf:type schema:DefinedTerm
129 N318e29b29cd54666a80c59e266aeaca9 rdf:first sg:person.01225701373.77
130 rdf:rest N4d90dce766bf49a392455428ae2a4300
131 N3d209178650f43cc86984ed79c9f6e4b rdf:first sg:person.01265262475.05
132 rdf:rest Nd442b7eb4b2942fdb00989046dfc08e7
133 N4446dc1c290d477aaf1493e502b2f209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Antineoplastic Combined Chemotherapy Protocols
135 rdf:type schema:DefinedTerm
136 N4d90dce766bf49a392455428ae2a4300 rdf:first sg:person.01054372611.40
137 rdf:rest rdf:nil
138 N7504b637daf2433aa9f7e45e3f173e64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pyrroles
140 rdf:type schema:DefinedTerm
141 N77bd84d34a754d17bf1f6e28b687453c rdf:first sg:person.0607771575.72
142 rdf:rest N318e29b29cd54666a80c59e266aeaca9
143 N793e11dbfd314c6d959d5b2cea2df41f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Kidney Neoplasms
145 rdf:type schema:DefinedTerm
146 N82742bee836249c08667b8623038a697 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antibodies, Monoclonal
148 rdf:type schema:DefinedTerm
149 N931a6b765cfc49a0821034e52c30db12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Carcinoma, Renal Cell
151 rdf:type schema:DefinedTerm
152 N9ae4d9231ad547bf9598e2185b6d3b86 schema:volumeNumber 101
153 rdf:type schema:PublicationVolume
154 N9dd85fb1f7034a6388c8c51abcf45191 rdf:first sg:person.0762650054.31
155 rdf:rest N3d209178650f43cc86984ed79c9f6e4b
156 Nb8484ee51c5f458fb58118a354960281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Sunitinib
158 rdf:type schema:DefinedTerm
159 Nbf9bedd04b0e4605ab9cfaa67e7e9b82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Disease-Free Survival
161 rdf:type schema:DefinedTerm
162 Nc045069290b244688f05b10e7e02f3b2 schema:name pubmed_id
163 schema:value 19568242
164 rdf:type schema:PropertyValue
165 Nc11a56dfbc0848c4af2b42d90b82a414 schema:name doi
166 schema:value 10.1038/sj.bjc.6605167
167 rdf:type schema:PropertyValue
168 Nc8986539095149e6948f2beb03973a5b schema:name dimensions_id
169 schema:value pub.1013222336
170 rdf:type schema:PropertyValue
171 Nc96cbaad282b408fbae523122a4a0e07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Interferon-alpha
173 rdf:type schema:DefinedTerm
174 Nd3255092b7b4490c83b1a4afc8851b1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antibodies, Monoclonal, Humanized
176 rdf:type schema:DefinedTerm
177 Nd442b7eb4b2942fdb00989046dfc08e7 rdf:first sg:person.0647332044.69
178 rdf:rest N1934035b895d4fa785ffeb081429cb26
179 Nddc0cb38b1e04289b84ebd1301072eb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Bevacizumab
181 rdf:type schema:DefinedTerm
182 Nde10a1bdbcf84b88b10232789f8151b5 schema:issueNumber 2
183 rdf:type schema:PublicationIssue
184 Ne8e66cbed7d94fa0b5dc4eb20d552cce rdf:first sg:person.01262712354.34
185 rdf:rest N77bd84d34a754d17bf1f6e28b687453c
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
190 schema:name Oncology and Carcinogenesis
191 rdf:type schema:DefinedTerm
192 sg:journal.1017082 schema:issn 0007-0920
193 1532-1827
194 schema:name British Journal of Cancer
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01054372611.40 schema:affiliation grid-institutes:grid.467855.d
198 schema:familyName Stein
199 schema:givenName K
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40
201 rdf:type schema:Person
202 sg:person.01174312663.64 schema:affiliation grid-institutes:grid.467855.d
203 schema:familyName Rogers
204 schema:givenName G
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64
206 rdf:type schema:Person
207 sg:person.01225701373.77 schema:affiliation grid-institutes:grid.5491.9
208 schema:familyName Welch
209 schema:givenName K
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225701373.77
211 rdf:type schema:Person
212 sg:person.01262712354.34 schema:affiliation grid-institutes:grid.467855.d
213 schema:familyName Green
214 schema:givenName C
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262712354.34
216 rdf:type schema:Person
217 sg:person.01265262475.05 schema:affiliation grid-institutes:grid.467855.d
218 schema:familyName Liu
219 schema:givenName Z
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265262475.05
221 rdf:type schema:Person
222 sg:person.0607771575.72 schema:affiliation grid-institutes:grid.467855.d
223 schema:familyName Moxham
224 schema:givenName T
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607771575.72
226 rdf:type schema:Person
227 sg:person.0647332044.69 schema:affiliation grid-institutes:grid.467855.d
228 schema:familyName Hoyle
229 schema:givenName M
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647332044.69
231 rdf:type schema:Person
232 sg:person.0762650054.31 schema:affiliation grid-institutes:grid.467855.d
233 schema:familyName Thompson Coon
234 schema:givenName J S
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650054.31
236 rdf:type schema:Person
237 sg:pub.10.1186/1471-2407-6-293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045174638
238 https://doi.org/10.1186/1471-2407-6-293
239 rdf:type schema:CreativeWork
240 sg:pub.10.1186/1471-2407-9-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011234840
241 https://doi.org/10.1186/1471-2407-9-34
242 rdf:type schema:CreativeWork
243 grid-institutes:grid.467855.d schema:alternateName Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
244 schema:name Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Plymouth and Exeter, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
245 rdf:type schema:Organization
246 grid-institutes:grid.5491.9 schema:alternateName Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK
247 schema:name Wessex Institute, University of Southampton, Mailpoint 728, SO16 7PX, Boldrewood, Southampton, UK
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...